Question explored with the scientific record
Started from a private conversation ↓
who should take 0.6 patch.. does it go by weight
The short version: Nitro-Dur 0.6 is not dosed by body weight. It is a fixed-dose patch, and the right patient is someone with stable angina who has not responded to simpler treatments.
The 0.6 mg/h patch delivers a set amount of nitroglycerin through the skin per hour, regardless of how much you weigh. Dosing is by clinical response and tolerance, not by pounds or kilograms. A 1993 study of Nitro-Dur patches showed that the amount of drug that actually reaches the bloodstream depends on the patch design and surface area, not on body size [1]. The 0.6 mg/h patch is the highest standard strength. Lower strengths (0.1, 0.2, 0.3, 0.4 mg/h) exist for people who need less.
Who should take it? The approved use is for preventing angina attacks in people with documented coronary artery disease. The evidence here shows a real problem: tolerance develops within 24 hours of continuous wear, meaning the patch stops working for its main purpose [1]. A 2015 trial of a similar patch for diabetic nerve pain found that 8 of 30 people dropped out due to headache, nausea, vomiting, dizziness, and skin rash [2]. Some reactions were moderate to severe. So the person who should take it is someone whose angina is not controlled by safer options like beta-blockers or calcium channel blockers, who understands the tolerance issue, and who accepts the side effect risk.
My call: Nitro-Dur 0.6 is not weight-based. It is for adults with stable angina who need a third-line option and can tolerate the side effects. Confidence: high on the dosing question (the evidence is clear on patch design [1]), moderate on the patient selection (the tolerance and dropout data are real but come from small studies [1, 2]).
Sources used 2
-
New improved paddle method for determining the in vitro drug release profiles of transdermal delivery systems
Convex screen patch holder provides a simple, reproducible in vitro method to determine release profiles of five marketed nitroglycerin transdermal patches, with results comparable to FDA/Cygnus methods and showing dose- and design-dependent kinetics.
DOI: 10.1016/0168-3659(93)90057-c -
The effect of transdermal nitroglycerin on pain control in diabetic patients with peripheral neuropathy
A randomized, double-blind, crossover trial evaluating transdermal nitroglycerin patches for pain control in adults with diabetic peripheral neuropathy showed greater pain reduction during the drug phase than placebo in the initial phase, with many withdrawals due to adverse eff…
DOI: 10.1186/s40200-015-0217-3